Recent developments include corporate actions such as a 1-for-10 reverse stock split and a $600,000 common stock offering. The company plans to launch a dry eye disease therapeutic device in China and has launched an N95 mask product. Regulatory progress includes candesartan tablets passing a generic-drug-consistency evaluation.

• China Pharma announced a 1-for-10 reverse stock split in April 2025 [N2].
• The company completed a $600,000 common stock offering in December 2024 [N3].
• China Pharma plans to launch a dry eye disease therapeutic device in China [N4].
• The company’s candesartan tablets passed a generic-drug-consistency evaluation [N5].
• China Pharma launched an N95 mask product [N6].

China Pharma has demonstrated regulatory progress with products such as candesartan tablets passing generic-drug-consistency evaluations and is expanding its product portfolio with launches like the dry eye disease therapeutic device and N95 masks. The company’s efforts to improve liquidity through stock offerings and reverse stock splits, along with management’s initiatives to optimize operations and reduce costs, may support operational stability. The Helpson brand recognition and established distributor relationships provide a foundation for market presence in China.

The company faces significant challenges including recurring net losses, negative gross margins, and liquidity constraints with current liabilities exceeding current assets. Its reliance on off-patent generics exposes it to intense competition and pricing pressure. Regulatory risks include potential production suspensions, product recalls, and evolving compliance requirements. Concentration risk exists due to dependence on a limited number of distributors. Material weaknesses in internal controls and substantial doubt about the company’s ability to continue as a going concern add to operational and financial risks.

China Pharma's competitive advantage is limited by its reliance on off-patent branded generic pharmaceuticals, which face substantial competition from other manufacturers including larger state-owned and foreign companies. The company’s Helpson brand provides some market recognition, but the lack of patent protection and the presence of multiple competitors with greater resources constrain its moat. Regulatory compliance and relationships with distributors are critical to maintaining market access, but these factors also introduce risks. Overall, the company operates in a highly competitive and regulated environment with limited barriers to entry for competitors.

• Regulatory Compliance Risks: Failure to meet Drug Administration Law standards or GMP requirements could lead to production suspensions and adversely affect operations and profitability.
• Competition and Market Risks: The company faces substantial competition from other pharmaceutical manufacturers, including foreign and state-owned companies, which may reduce sales and margins.
• Product Recall and Liability Risks: Product cessations or recalls initiated by the company or regulatory authorities could impose significant costs and harm reputation and revenue.
• Liquidity and Financial Risks: Recurring losses, negative gross margins, and current liabilities exceeding current assets raise substantial doubt about the company’s ability to continue as a going concern.
• Distributor Concentration Risk: Dependence on a limited number of distributors for the majority of sales creates risk if relationships are disrupted or not renewed.
• Operational and Internal Control Risks: Material weaknesses in internal control over financial reporting may affect reliable financial reporting and investor confidence.
• Geopolitical and Regulatory Risks in China: Adverse changes in PRC government policies, legal uncertainties, and regulatory interventions could negatively impact business operations and financial results.

• China Pharma Holdings, Inc. is a Nevada holding company with all operations conducted in the People's Republic of China through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson).
• Helpson develops, manufactures, and markets pharmaceutical products for human use, including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
• Most products are prescription-based and approved by the National Medical Products Administration (NMPA) in China for at least one therapeutic indication.
• The company sells its products exclusively to pharmaceutical distributors in China and relies on these distributors for all revenues.
• China Pharma's products include off-patent branded generics, which face substantial competition from other manufacturers, including foreign and state-owned companies.
• The company’s Helpson brand is important for its market recognition and competitive advantage.
• China Pharma's products are subject to strict regulatory standards, including compliance with the Drug Administration Law and GMP standards; failure to meet these can lead to production suspensions.
• The company faces risks from product recalls or cessations initiated by itself or the NMPA, which can impose significant costs and affect revenue.
• The company’s growth depends on successful marketing to hospitals and selection in tender processes.
• China Pharma has experienced negative gross margins, with a gross loss of approximately -3.2% for the year ended December 31, 2025, reflecting challenges in cost structure and pricing.
• The company’s revenue for the fiscal year ended December 31, 2025 was approximately $4.14 million, with a net loss of about $3.19 million and basic and diluted EPS of -$0.74 per share.
• As of December 31, 2025, China Pharma had cash and cash equivalents of approximately $345,000, current assets of about $2.35 million, and current liabilities of about $7.4 million, resulting in a current ratio of 0.32 and a cash ratio of 0.05, indicating liquidity constraints.
• The company has an accumulated deficit exceeding $45 million as of late 2025 and has reported recurring losses raising substantial doubt about its ability to continue as a going concern.
• Management is implementing measures to improve liquidity, including enhancing sales models, strengthening accounts receivable collection, exploring strategic alternatives, and cost reduction initiatives across procurement, production, human resources, and marketing.
• Recent corporate actions include a 1-for-10 reverse stock split announced in April 2025 and a $600,000 common stock offering announced in December 2024.
• China Pharma plans to launch a dry eye disease therapeutic device in China and has launched an N95 mask product.
• The company’s candesartan tablets passed a generic-drug-consistency evaluation, indicating regulatory progress for some products.
• The company’s operations and financial results are subject to risks related to the regulatory environment in China, including government intervention, legal uncertainties, and compliance with evolving laws.
• China Pharma relies on a limited number of distributors for the majority of its sales, which poses concentration risk.
• The company has limited insurance coverage and may incur losses from product liability claims or business interruptions.
• The company has identified material weaknesses in internal control over financial reporting, which may affect reliable reporting and investor confidence.